PFE - Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era | Benzinga
Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. But, in a post-pandemic world, Pfizer and Moderna shares lost about 30% of their respective value over the past year. Yet, these struggling pharma companies are promising to turn the tide with their new long-term focus on oncology. Moreover, smaller companies like Mainz Biomed N.V. (NASDAQ: MYNZ) already broke ground when it comes to revolutionizing cancer treatment.
Pfizer might be down, but it is certainly not out.
Throughout 2023, Pfizer made big moves to turn its growth story around with looming concerns of $17 billion in lost sales due to its blockbusters outside the COVID-19 range set to lose exclusivity this decade. Along with promising acquisitions, Pfizer is completing its biggest ever wave of product launches. By purchasing the oncology specialist Seagen, Pfizer gained four commercialized products with sales on the rise and a valuable opportunity to strengthen its positioning in cancer treatment. By the end of the decade, Pfizer is expecting its ...